Abstract
- Background
The dried root extract of Astragalus membranaceus, widely known as Astragali radix, is a prominent botanical therapeutic in traditional Chinese medicine, celebrated for its diverse health benefits and well-established safety profile. Pharmacological evaluations demonstrate that Astragalus root extract exhibits robust bioactive properties, including anti-inflammatory, antioxidant, antiviral, and hepatoprotective effects. Leveraging these multifaceted protective mechanisms, current biomedical research is investigating its novel application as a complementary nutraceutical remedy in the management of degenerative joint disorders such as osteoarthritis. This in vitro study was designed to evaluate the molecular efficacy of an Astragalus membranaceus hydroalcoholic root extract in modulating inflammatory and catabolic pathways using the HTB-94 human chondrocyte cell line.
- Methods
A controlled in vitro experimental study was conducted utilizing the HTB-94 human chondrocyte cell line, a well-established cellular model for investigating inflammatory and osteoarthritic pathways. Cultured cells were treated with Astragalus membranaceus hydroalcoholic root extract at concentrations of 0.01 and 0.1 mg/mL in the presence or absence of tumor necrosis factor-$\alpha$ (TNF-$\alpha$) stimulation to induce an inflammatory state. Comprehensive molecular and biochemical assays were systematically performed. mRNA expression modulation levels were quantified using quantitative real-time polymerase chain reaction (qRT-PCR), while extracellular protein secretion levels were measured using Enzyme-Linked Immunosorbent Assay (ELISA) techniques. Evaluated primary endpoints included pro-inflammatory cytokines (Interleukin-6 [IL-6], Interleukin-1$\beta$ [IL-1$\beta$], and Interleukin-8 [IL-8]) and key cartilage matrix-degrading enzymes (Matrix Metalloproteinase-3 [MMP-3], Matrix Metalloproteinase-13 [MMP-13], and ADAMTS-5), alongside basal-level safety assessments in non-stimulated cells.
- Results
Treatment with Astragalus membranaceus root extract demonstrated potent anti-inflammatory and anti-catabolic efficacy without disrupting basal cellular homeostasis:
Attenuation of Pro-inflammatory Mediators: The extract significantly decreased the TNF-$\alpha$-induced inflammatory response by effectively downregulating both the mRNA expression and protein secretion of key pro-inflammatory cytokines, including IL-6, IL-1$\beta$, and IL-8.
Suppression of Matrix-Degrading Enzymes: Astragalus root extract administration robustly inhibited the catabolic degradation pathways by downregulating the expression and release of critical matrix metalloproteinases and aggrecanases, specifically MMP-3, MMP-13, and ADAMTS-5.
Preservation of Basal Homeostasis: Evaluations in non-TNF-$\alpha$-stimulated cells confirmed that the extract did not alter baseline physiological levels of interleukins or matrix metalloproteinases, highlighting selective therapeutic targeting.
Safety & Profile: The findings underscore a highly favorable safety profile, confirming the extract's potential as a safe and efficacious nutraceutical intervention.
- Conclusions
Astragalus membranaceus hydroalcoholic root extract effectively mitigates TNF-$\alpha$-induced inflammatory responses and catabolic enzyme expression in human chondrocytes while preserving basal cellular homeostasis. These empirical findings strongly support the therapeutic potential of Astragalus membranaceus extract as a safe and effective nutraceutical agent for joint health support and the complementary management of inflammatory joint disorders.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12468023/